Business NewsPR NewsWire • Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small...

View More : https://www.prnewswire.com:443/news-releases/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a...
Releted News by prnewswire
Los Angeles Regional Food Bank to Receive Hunger Is Donations Made at Local Albertsons Stores
Head of SunTours Caribbean Wins Illustrious Award with Business Worldwide Magazine
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Viasat Introduces Direct Cloud Connect: A New Service Providing Fast, Secure, Private Connections to Business-Critical Cloud Services
Ar├želik Calls For Industry to Lead on Plastic Waste at IFA 2019
Veoneer Nominated to Supply Global Automaker With Next Generation Vision System